PRIVACY POLICY

Effective Date: October 1, 2008

Purpose of the Privacy Statement

Bristol-Myers Squibb & Gilead Sciences, LLC respect the privacy of visitors to this Web site and understand that information about you, your health, and your health care is sensitive. Except as provided in the Transfer of Control section of this Web site's Internet Privacy Statement, Bristol-Myers Squibb & Gilead Sciences, LLC will not sell or rent your personally identifiable information. Bristol-Myers Squibb & Gilead Sciences, LLC developed this Internet Privacy Statement to provide information about our practices regarding the collection, use, and disclosure of information that you may provide when you visit this Web site. We encourage you to read this Internet Privacy Statement before using this Web site or submitting information. By using this Web site, you acknowledge that you understand and agree to the terms of the Internet Privacy Statement.

Policy on Use of Social Security Numbers

Bristol-Myers Squibb & Gilead Sciences, LLC have a policy which provides for the proper use and protection of Social Security numbers obtained in the course of doing business by Bristol-Myers Squibb & Gilead Sciences, LLC. Such policy protects the confidentiality of Social Security numbers, prohibits unlawful disclosure of Social Security numbers, and limits access to Social Security numbers. This policy applies to all methods of collection of Social Security numbers, including Social Security numbers obtained by oral, written and electronic means.

Information Voluntarily Provided by Users

You can visit much of the Web site without telling us who you are or providing us with other personally identifiable information. Some areas of the Web site allow you to contact us to ask questions or provide comments. When you communicate with us and request a response, we ask for your name and contact information. We intend to let you know how we will use such information before we collect it from you; if you tell us that you do not want us to use this information to make further contact with you beyond fulfilling your requests, we will respect your wishes. Some areas of the Web site may also require that you submit information in order to access specific content, features, interactive tools, services or participate in a particular activity. For example, to create an online account or to subscribe to a newsletter, we may ask for your name, contact information, and perhaps additional information so we can tailor our response to your request. In addition, when you access certain interactive tools or services, you may be asked to provide personally identifiable information. You may always choose not to provide the required information, but then you may not be able to participate in the particular activity that requires the information.

Use and Disclosure of Your Personally Identifiable Information That You Provide Voluntarily

We may personalize and customize this Web site for certain visitors. If you provide information about yourself via a contact form, you may find it customized with references to products and/or services that we believe may be of interest to you, based on your previous interactions and information you have provided to us. If you do provide us with personally identifiable information, such as your name, postal address, e-mail address, telephone number, or other information such as your education level, or personal medical information, you agree that we may contact you through a variety of means such as postal mail, phone, or e-mail to provide you with information we believe may be of interest to you unless you opt out of this service by contacting us as indicated below. If you opt-in to the Bristol-Myers Squibb & Gilead Sciences, LLC program, we may share your information with one of our other Bristol-Myers Squibb & Gilead Sciences, LLC companies who might invite you to participate in one of their programs. If you do not opt out of this service, we may also share this information with providers of services to Bristol-Myers Squibb & Gilead Sciences, LLC who help Bristol-Myers Squibb & Gilead Sciences, LLC to develop programs and provide services that may be of interest to you, or for information processing, mailing, and/or Internet-based delivery purposes. Except as provided in the Transfer of Control section, Bristol-Myers Squibb & Gilead Sciences, LLC will not sell or rent your personally identifiable information. In addition, as stated in the Transfer of Control section, your personally identifiable information may be shared with actual or potential parties to a contemplated transaction where we decide to reorganize or divest part or all of a business or a line of our business, without obtaining your consent or any further notice to you. In such circumstances, we will seek written assurances that personally identifiable information submitted through this Web site will be protected appropriately.

Use and Disclosure of Non-Personally Identifiable Information

Bristol-Myers Squibb & Gilead Sciences, LLC will not treat as confidential any information that you provide that is not personally identifiable, such as questions, comments, ideas, or suggestions. You should be aware that Bristol-Myers Squibb & Gilead Sciences, LLC will be free to disclose through any means and use for any purpose such information in its sole discretion. By providing such information to Bristol-Myers Squibb & Gilead Sciences, LLC, you understand and agree that no relationship has been created between Bristol-Myers Squibb & Gilead Sciences, LLC and you, and Bristol-Myers Squibb & Gilead Sciences, LLC have no obligation to you whatsoever regarding that information.

Update and Correction of Personally Identifiable Information

You may contact us to update or correct much of your personally identifiable information that you provide to us through the Web site other than the limited information described below under the Regulatory Requirements section, or to opt-out from our mailings and other services that you may have signed up for. To do so, please contact us at (877) 274-0626.

Security

We take reasonable precautions to maintain the protection of personally identifiable information collected through this Web site and used in accordance with this Privacy Statement. In addition to technical safeguards, we also use physical controls and procedures to safeguard your personally identifiable information. However, we cannot guarantee that it is completely secure from people who might attempt to evade our security measures or intercept transmissions over the Internet.

Use of Cookies

We may store some information on your computer using a technique your browser supports called "cookies". The cookies are used for a variety of purposes, including but not limited to helping you log in (e.g., remembering your user name if you register or log in), remembering some of your customized user preferences, to help us better understand how people use our Web site, to collect anonymous traffic data, and to help us improve our Web site. In some cases, this information will help us tailor content to your interests or help us avoid asking for the same information when you revisit our Web site. The cookies set by our Web sites are used only by our Web sites. With respect to collecting anonymous traffic data, we may use third parties to collect such data on our behalf. To disable or limit the use of cookies, please refer to the options provided by your Internet browser. If you do so, however, some pages on this Web site may not work properly.

Web Beacons

A Web Beacon is a clear GIF (Graphics Interchange Format) image or pixel tag (also known as a "Web beacon") that companies place on their Web sites to allow an Internet advertising or audience measurement company to help them analyze their advertising campaigns and general usage patterns of visitors to their Web sites. Bristol-Myers Squibb & Gilead Sciences, LLC use Web beacons on some of their Web sites. Subject to the transfer of control situation described below, Bristol-Myers Squibb & Gilead Sciences, LLC will not sell or rent your personally identifiable information.

Web Server Logging and IP Addresses

With or without cookies, our Web site keeps track of usage data, such as the source address that a page request is coming from (i.e., your IP address, domain name), date and time of the page request, the referring Web site (if any), and other parameters in the URL (e.g., search criteria). We use this data to better understand Web site usage on the whole and to determine which areas of our Web site users prefer (e.g., based on the number of visits to those areas). This information is stored in log files and is used by Bristol-Myers Squibb & Gilead Sciences, LLC for statistical reporting.

Transfer of Control

Circumstances may arise where we decide to reorganize or divest part or all of our business or of a line of our business, including our information databases and Web sites, through a sale, divestiture, merger, acquisition, or other means of transfer. In any such circumstance, personally identifiable information may be shared with, sold, transferred, rented, licensed or otherwise provided or made available by us or on our behalf to actual or potential parties to, and in connection with, the contemplated transaction without your consent or any further notice to you. In such circumstances, we will seek written assurances that personally identifiable information submitted through this Web site will be protected appropriately.

Regulatory Requirements

If you contact us regarding your experience with using any of our products, we may use the information you provide in submitting reports to the U.S. Food and Drug Administration, and as otherwise required of us by law or governmental audit. We may also use the information to contact your healthcare professional to follow up regarding an unexpected event involving the use of any one of our products. You understand that in order to comply with the law, Bristol-Myers Squibb & Gilead Sciences, LLC may not be permitted to comply with your request to amend or remove personally identifiable information that was provided to Bristol-Myers Squibb & Gilead Sciences, LLC by a healthcare professional or a consumer regarding an adverse event or reaction involving medicine, medical products or medical devices.

Law Enforcement

In rare situations, we may be required by court order or other legal or regulatory process, or as otherwise required by law to divulge personally identifiable information to law enforcement authorities, the courts, or regulatory authorities. Bristol-Myers Squibb & Gilead Sciences, LLC will cooperate in responding to such requests, in accordance with the regulatory or legal process, and will take appropriate measures to ensure that the requester understands the sensitive nature of any health-related personally identifiable information they receive.

Privacy Policies Governing Linked Web Sites

As a convenience to our visitors, the Web site contains links to other Web sites that may offer useful information. The Internet Privacy Statement described here does not apply to your use of those other Web sites. Before using the linked Web sites, please review their Internet privacy statements to understand how they use and protect personally identifiable information.

Changes in Our Privacy Statement

Bristol-Myers Squibb & Gilead Sciences, LLC may at any time revise this Privacy Statement by updating this posting. You are bound by any such revisions and should therefore periodically visit this page to review the most current Privacy Statement.

Online Privacy for Children

We are committed to protecting the privacy of children. We do not intend to collect personally identifiable information from children under 18 years old. If a child has provided us with personally identifiable information, the parent or guardian of that child may contact us at (877) 274-0626.

Questions

If you have any questions about the Web site’s Internet Privacy Statement or other aspects of privacy on our Web site, please contact us at (877) 274-0626.

Additional IMPORTANT SAFETY INFORMATION for
ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

Who should not take ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate)?

You and your healthcare provider should decide if ATRIPLA is right for you. Do not take ATRIPLA if you are allergic to ATRIPLA or any of its ingredients.

What should I tell my healthcare provider before taking
ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate)?

Tell your healthcare provider if you:

  • Are pregnant or planning to become pregnant: Women should not become pregnant while taking ATRIPLA and for 12 weeks after stopping ATRIPLA. Serious birth defects have been seen in children of women treated during pregnancy with one of the medicines in ATRIPLA. Women must use a reliable form of barrier contraception, such as a condom or diaphragm, even if they also use other methods of birth control, while on ATRIPLA and for 12 weeks after stopping ATRIPLA. Women should not rely only on hormone-based birth control, such as pills, injections, or implants, because ATRIPLA may make these contraceptives ineffective.
  • Are breastfeeding: Women with HIV should not breastfeed because they can pass HIV and some of the medicines in ATRIPLA through their milk to the baby. We do not know if ATRIPLA could harm your baby.
  • Have kidney problems or are undergoing kidney dialysis treatment
  • Have bone problems
  • Have liver problems, including hepatitis B or C virus infection. Your healthcare provider may want to do tests to check your liver while you take ATRIPLA or may switch you to another medicine.
  • Have ever had mental illness or are using drugs or alcohol
  • Have ever had seizures or are taking medicine for seizures. Seizures have occurred in patients taking efavirenz, a component of ATRIPLA, generally in those with a history of seizures. If you have ever had seizures, or take medicine for seizures, your healthcare provider may want to switch you to another medicine or monitor you.

What important information should I know about taking other medicines with
ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate)?

ATRIPLA may change the effect of other medicines, including the ones for HIV-1, and may cause serious side effects. Your healthcare provider may change your other medicines or change their doses.

MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA

  • Do not take ATRIPLA if you are taking the following medicines because serious and life-threatening side effects may occur when taken together: Vascor® (bepridil), Propulsid® (cisapride), Versed® (midazolam), Orap® (pimozide), Halcion® (triazolam), or ergot medications (for example, Wigraine® and Cafergot®).
  • ATRIPLA should not be taken with: Combivir® (lamivudine/zidovudine),
    COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate),
    EMTRIVA® (emtricitabine), Epivir® or Epivir-HBV® (lamivudine),
    Epzicom® (abacavir sulfate/lamivudine),
    STRIBILD® (elvitegravir/cobicistat/emtricitabine/tenofovir DF),
    Trizivir® (abacavir sulfate/lamivudine/zidovudine),
    TRUVADA® (emtricitabine/tenofovir DF), or VIREAD® (tenofovir DF), because they contain the same or similar active ingredients as ATRIPLA. ATRIPLA should not be used with
    SUSTIVA® (efavirenz) unless recommended by your healthcare provider.
  • Vfend® (voriconazole) should not be taken with ATRIPLA since it may lose its effect or may increase the chance of having side effects from ATRIPLA.
  • Do not take St. John’s wort (Hypericum perforatum), or products containing St. John’s wort with ATRIPLA. Taking St. John’s wort may decrease ATRIPLA levels and lead to increased viral load, and possible resistance to ATRIPLA or cross-resistance to other anti-HIV-1 drugs.
  • ATRIPLA should not be used with HEPSERA® (adefovir dipivoxil).

These are not all the medicines that may cause problems if you take ATRIPLA. Tell your healthcare provider about all prescription and nonprescription medicines, vitamins, or herbal supplements you are taking or plan to take.

What are the possible side effects of
ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate)?

ATRIPLA may cause the following additional serious side effects:

  • Serious psychiatric problems. Severe depression, strange thoughts, or angry behavior have been reported by a small number of patients. Some patients have had thoughts of suicide, and a few have actually committed suicide. These problems may occur more often in patients who have had mental illness.
  • Kidney problems (including decline or failure of kidney function). If you have had kidney problems, or take other medicines that may cause kidney problems, your healthcare provider should do regular blood tests. Symptoms that may be related to kidney problems include a high volume of urine, thirst, muscle pain, and muscle weakness.
  • Other serious liver problems. Some patients have experienced serious liver problems, including liver failure resulting in transplantation or death. Most of these serious side effects occurred in patients with a chronic liver disease such as hepatitis infection, but there have also been a few reports in patients without any existing liver disease.
  • Changes in bone mineral density (thinning bones). Lab tests show changes in the bones of patients treated with tenofovir DF, a component of ATRIPLA. Some HIV patients treated with tenofovir DF developed thinning of the bones (osteopenia), which could lead to fractures. Also, bone pain and softening of the bone (which may lead to fractures) may occur as a consequence of kidney problems. If you have had bone problems in the past, your healthcare provider may want to do tests to check your bones or may prescribe medicines to help your bones. Also, bone pain and bone softening may occur because of kidney problems.

Common side effects:

  • Patients may have dizziness, headache, trouble sleeping, drowsiness, trouble concentrating, and/or unusual dreams during treatment with ATRIPLA. These side effects may be reduced if you take ATRIPLA at bedtime on an empty stomach; they tend to go away after taking ATRIPLA for a few weeks. Tell your healthcare provider right away if any of these side effects continue or if they bother you. These symptoms may be more severe if ATRIPLA is used with alcohol and/or mood-altering (street) drugs.
  • If you are dizzy, have trouble concentrating, and/or are drowsy, avoid activities that may be dangerous, such as driving or operating machinery.
  • Rash is a common side effect with ATRIPLA that usually goes away without any change in treatment. Rash may be serious in a small number of patients. Rash occurs more commonly in children and may be a serious problem. If a rash develops, call your healthcare provider right away.
  • Other common side effects include: tiredness, upset stomach, vomiting, gas, and diarrhea.

Other possible side effects:

  • Changes in body fat have been seen in some people taking anti-HIV-1 medicines. Increase of fat in the upper back and neck, breasts, and around the trunk may happen. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these changes in body fat are not known.
  • Skin discoloration (small spots or freckles) may also happen.
  • In some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. If you notice any symptoms of infection, contact your healthcare provider right away.
  • Additional side effects are inflammation of the pancreas, allergic reaction (including swelling of the face, lips, tongue, or throat), shortness of breath, pain, stomach pain, weakness, and indigestion.

This is not a complete list of side effects. Tell your healthcare provider or pharmacist if you notice any side effects while taking ATRIPLA (efavirenz/emtricitabine/tenofovir disoproxil fumarate).

You should take ATRIPLA once daily on an empty stomach. Taking ATRIPLA at bedtime may make some side effects less bothersome.

Please see Full Prescribing Information, including “What is the most important information I should know about ATRIPLA” in the Patient Information section.

Bristol-Myers Squibb    Gilead

© 2014 Bristol-Myers Squibb Company.

ATRIPLA is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. SUSTIVA is a registered trademark of Bristol-Myers Squibb Pharma Company. COMPLERA, EMTRIVA, GILEAD, GSI, HEPSERA, STRIBILD, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.

697US13BR03378-01-01 01/14